Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
303 questions in 64 reviews · Hepato-Biliary
current versionsNo studies 303 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
D‐Penicillamine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
D‐Penicillamine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid (UDCA) vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid (UDCA) vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Azathioprine vs no intervention Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Azathioprine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Azathioprine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Short‐term and medium‐term mortality · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Adverse events · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Quality of life · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Disease recurrence · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Length of hospital stay · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous alcohol injection vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Laser ablation vs radiofrequency ablation Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Laser ablation vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Surgery vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Lactulose vs lactitol Quality of life (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR There was no evidence of differences in the number of serious adverse events for any of the comparisons Quality of evidence = very low1,2,3. · people undergoing liver resection Methods to decrease blood loss during liver resection: a network meta‐analysis (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR None of the trials reported this outcome at any time point. · people undergoing liver resection Methods to decrease blood loss during liver resection: a network meta‐analysis (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR PEI versus PAI · hospitalised people with early HCC treated with PEI, PAI, or surgery. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number and type of adverse events · hospitalised people with early HCC treated with PEI, PAI, or surgery. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · hospitalised people with early HCC treated with PEI, PAI, or surgery. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR PEI versus surgery · hospitalised people with early HCC treated with PEI, PAI, or surgery. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma (2015) · Cochrane | no estimate extracted | NR | No studies |
Various interventions vs control Opioids versus NSAIDs · people undergoing laparoscopic cholecystectomy Pharmacological interventions for prevention or treatment of postoperative pain in people undergoing… (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospital stay · people undergoing laparoscopic cholecystectomy Methods of intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomy (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Variceal bleeding 5 years · patients with chronic hepatitis C who have failed prior antiviral therapy and who have severe histologic disease… Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Ascites 5 years · patients with chronic hepatitis C who have failed prior antiviral therapy and who have severe histologic disease… Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interferon vs. control · patients undergoing liver transplantation for chronic hepatitis C viral infection. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interferon vs. control · patients undergoing liver transplantation for chronic hepatitis C viral infection. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver… (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious adverse events ‐ Haemodilution versus control. · patients with liver resection. Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resection (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically apparent hepatitis A ( · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hepatitis A‐related mortality · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (low risk of bias) Maiwald 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (all included trials) Maiwald 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious local adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious systemic adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A. Hepatitis A immunisation in persons not previously exposed to hepatitis A (2012) · Cochrane | no estimate extracted | NR | No studies |